S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.48 (+0.30%)
AAPL   174.10 (-0.26%)
MSFT   290.01 (-0.45%)
META   174.55 (-0.17%)
GOOGL   119.90 (+0.29%)
AMZN   142.33 (+0.16%)
TSLA   908.01 (-0.44%)
NVDA   187.96 (+2.51%)
NIO   19.88 (-1.00%)
BABA   90.55 (+0.87%)
AMD   100.38 (+2.15%)
MU   62.95 (+2.16%)
T   18.43 (+0.05%)
CGC   3.80 (-6.40%)
F   16.15 (+0.75%)
GE   79.23 (-0.86%)
DIS   122.67 (-0.11%)
AMC   19.37 (-9.32%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.81 (+1.52%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.48 (+0.30%)
AAPL   174.10 (-0.26%)
MSFT   290.01 (-0.45%)
META   174.55 (-0.17%)
GOOGL   119.90 (+0.29%)
AMZN   142.33 (+0.16%)
TSLA   908.01 (-0.44%)
NVDA   187.96 (+2.51%)
NIO   19.88 (-1.00%)
BABA   90.55 (+0.87%)
AMD   100.38 (+2.15%)
MU   62.95 (+2.16%)
T   18.43 (+0.05%)
CGC   3.80 (-6.40%)
F   16.15 (+0.75%)
GE   79.23 (-0.86%)
DIS   122.67 (-0.11%)
AMC   19.37 (-9.32%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.81 (+1.52%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.48 (+0.30%)
AAPL   174.10 (-0.26%)
MSFT   290.01 (-0.45%)
META   174.55 (-0.17%)
GOOGL   119.90 (+0.29%)
AMZN   142.33 (+0.16%)
TSLA   908.01 (-0.44%)
NVDA   187.96 (+2.51%)
NIO   19.88 (-1.00%)
BABA   90.55 (+0.87%)
AMD   100.38 (+2.15%)
MU   62.95 (+2.16%)
T   18.43 (+0.05%)
CGC   3.80 (-6.40%)
F   16.15 (+0.75%)
GE   79.23 (-0.86%)
DIS   122.67 (-0.11%)
AMC   19.37 (-9.32%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.81 (+1.52%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.48 (+0.30%)
AAPL   174.10 (-0.26%)
MSFT   290.01 (-0.45%)
META   174.55 (-0.17%)
GOOGL   119.90 (+0.29%)
AMZN   142.33 (+0.16%)
TSLA   908.01 (-0.44%)
NVDA   187.96 (+2.51%)
NIO   19.88 (-1.00%)
BABA   90.55 (+0.87%)
AMD   100.38 (+2.15%)
MU   62.95 (+2.16%)
T   18.43 (+0.05%)
CGC   3.80 (-6.40%)
F   16.15 (+0.75%)
GE   79.23 (-0.86%)
DIS   122.67 (-0.11%)
AMC   19.37 (-9.32%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.81 (+1.52%)
NASDAQ:ALIM

Alimera Sciences - ALIM Stock Forecast, Price & News

$7.04
+0.35 (+5.23%)
(As of 08/18/2022 03:02 PM ET)
Add
Compare
Today's Range
$7.04
$7.80
50-Day Range
$5.05
$7.70
52-Week Range
$3.94
$7.92
Volume
840 shs
Average Volume
21,298 shs
Market Capitalization
$49.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Alimera Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
40.8% Upside
$10.00 Price Target
Short Interest
Healthy
0.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.12mentions of Alimera Sciences in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.85) to ($0.57) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

244th out of 1,122 stocks

Pharmaceutical Preparations Industry

110th out of 551 stocks

ALIM stock logo

About Alimera Sciences (NASDAQ:ALIM) Stock

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Alimera Sciences Stock Down 0.1 %

Shares of Alimera Sciences stock opened at $6.69 on Thursday. The company has a 50 day moving average of $5.73 and a 200-day moving average of $5.44. Alimera Sciences has a 1-year low of $3.94 and a 1-year high of $7.92.

Alimera Sciences (NASDAQ:ALIM - Get Rating) last issued its quarterly earnings results on Wednesday, July 27th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.16. During the same period in the prior year, the business posted $0.76 earnings per share. As a group, equities analysts forecast that Alimera Sciences will post -1.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ALIM. HC Wainwright boosted their price target on Alimera Sciences from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Thursday, July 28th. StockNews.com initiated coverage on Alimera Sciences in a research report on Wednesday. They set a "hold" rating for the company.

Receive ALIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter.

ALIM Stock News Headlines

Russia Ignites West's Battle for Energy Independence
Putin's invasion of Ukraine has revealed the West's dependence on Russia for their energy needs. Western countries are now scrambling for stable, renewable energy. World leaders must find new sources of minerals, such as copper, essential to their transition to energy independence.
Russia Ignites West's Battle for Energy Independence
Putin's invasion of Ukraine has revealed the West's dependence on Russia for their energy needs. Western countries are now scrambling for stable, renewable energy. World leaders must find new sources of minerals, such as copper, essential to their transition to energy independence.
See More Headlines
Receive ALIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter.

ALIM Company Calendar

Last Earnings
7/27/2022
Today
8/18/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALIM
Employees
145
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+42.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-4,370,000.00
Pretax Margin
-33.35%

Debt

Sales & Book Value

Annual Sales
$59.03 million
Book Value
($4.51) per share

Miscellaneous

Free Float
6,094,000
Market Cap
$49.28 million
Optionable
Optionable
Beta
1.41

Social Links















ALIM Stock - Frequently Asked Questions

Should I buy or sell Alimera Sciences stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALIM shares.
View ALIM analyst ratings
or view top-rated stocks.

What is Alimera Sciences' stock price forecast for 2022?

1 equities research analysts have issued 1 year price objectives for Alimera Sciences' shares. Their ALIM share price forecasts range from $9.00 to $11.00. On average, they predict the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 49.5% from the stock's current price.
View analysts price targets for ALIM
or view top-rated stocks among Wall Street analysts.

How have ALIM shares performed in 2022?

Alimera Sciences' stock was trading at $5.13 at the beginning of 2022. Since then, ALIM stock has increased by 30.4% and is now trading at $6.69.
View the best growth stocks for 2022 here
.

When is Alimera Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our ALIM earnings forecast
.

How were Alimera Sciences' earnings last quarter?

Alimera Sciences, Inc. (NASDAQ:ALIM) announced its earnings results on Wednesday, July, 27th. The biopharmaceutical company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.61) by $0.16. During the same period last year, the company posted $0.76 earnings per share.

When did Alimera Sciences' stock split?

Shares of Alimera Sciences reverse split on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Rick Eiswirth's approval rating as Alimera Sciences' CEO?

2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alimera Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB).

What is Alimera Sciences' stock symbol?

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

Who are Alimera Sciences' major shareholders?

Alimera Sciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.83%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James R Largent, John Philip Jones, John Snisarenko, Philip Ashman, Richard S Eiswirth Jr and Stanley Morgan.
View institutional ownership trends
.

How do I buy shares of Alimera Sciences?

Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alimera Sciences' stock price today?

One share of ALIM stock can currently be purchased for approximately $6.69.

How much money does Alimera Sciences make?

Alimera Sciences (NASDAQ:ALIM) has a market capitalization of $46.83 million and generates $59.03 million in revenue each year. The biopharmaceutical company earns $-4,370,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis.

How many employees does Alimera Sciences have?

The company employs 145 workers across the globe.

When was Alimera Sciences founded?

Alimera Sciences was founded in 2003.

How can I contact Alimera Sciences?

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The official website for the company is www.alimerasciences.com. The biopharmaceutical company can be reached via phone at (678) 990-5740, via email at scottg@coreir.com, or via fax at 678-990-5744.

This page (NASDAQ:ALIM) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.